Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third TargetC4T to Develop Degraders With ...
April 9 (Reuters) - C4 Therapeutics said on Thursday it has entered into a deal focused on research and development of a type ...
C4 Therapeutics (CCCC) on Thursday announced a new collaboration with its long-standing partner Roche (RHHBY) (RHHBF) to ...
Sidewinder Therapeutics’ bispecific antibody-drug conjugates target pairs of receptors found on cancer cells, which the ...
Three years after its OrbiMed-backed series A in 2023, Sidewinder Therapeutics is adding to its nest egg courtesy of a clutch ...
Gilead’s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and ...
DUBLIN--(BUSINESS WIRE)--The "Bispecific Antibody Drug Conjugates Clinical Trials, Development Platforms, Competitive Landscape & Market Opportunity Insight 2025" report has been added to ...
According to MarketsandMarkets™, the Next Generation Drug Conjugates Market is projected to grow from about USD 15.75 billion in 2026 to USD 42.55 billion by 2035, at a CAGR of 11.7%.
The conjugate space is evolving fast - moving beyond traditional ADCs into new formats like degrader-conjugates, oligonucleotide conjugates, bispecific ADCs, and more. The 4 th Novel Conjugates Summit ...
5d
Next Generation Drug Conjugates (NDCs) Market worth $42.55 billion by 2035 | MarketsandMarkets(TM)
According to MarketsandMarkets(TM), the Next Generation Drug Conjugates Market is projected to grow from about USD 15.75 billion in 2026 to USD 42.55 billion by 2035, at a CAGR of 11.7%. Browse 260 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results